Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Uterine leiomyosarcoma may be rare, but awareness can save lives. If you or someone you love is experiencing persistent or ...

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial.

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Postmenopausal bleeding is also a sign of uterine cancer and she urged, “If you see a blood, rush to the doctor.” Loss of appetite is a sign of ovarian cancer. Dr Nompumelelo also said lifestyle ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Canada is among countries that have made it a goal to eliminate cervical cancer by or before 2040, but between 2015 and 2019 ...

Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously ...

Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR ...

Claire O'Shea, 42, from Cardiff, was diagnosed with irritable bowel syndrome (IBS) but a masseuse on a Turkish holiday told ...

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

A “crisis” in cancer treatment wait times has prompted the opening of a second operating room for gynecological cancers at ...